Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The eradication rate of the standard H. pylori eradication therapy (such as the triple therapy with a proton pump inhibitor [PPI], amoxicillin and clarithromycin) depends on bacterial susceptibility to clarithromycin and genotypes of CYP2C19 in patients. The investigators intend to investigate whether the tailored therapy based on the two above-mentioned factors increases the cure rate of the initial eradication therapy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hamamatsu University
• Collaborator: Yokoyama Foundation for Clinical Pharmacology
• Treatments: Amoxicillin; Clarithromycin; Dexlansoprazole; Lansoprazole

Criteria

Inclusion Criteria:

• Patients with H. pylori infection

Exclusion Criteria:

• Patients without H. pylori infection